|
Patent landscape, scope, and claims: |
Analysis of US Patent 7,414,105: Scope, Claims, and Patent Landscape
What Does US Patent 7,414,105 Cover?
US Patent 7,414,105, granted August 26, 2008, assigns rights primarily to Amgen Inc. The patent is titled "Sustained-release erythropoietin formulations," focusing on long-acting forms of erythropoietin (EPO), a glycoprotein hormone used in anemia treatment.
Patent Scope
The patent covers methods and compositions for administering erythropoietin with controlled, sustained-release properties. Key aspects include:
- Formulation Components: Compositions comprising EPO and biodegradable or biocompatible sustained-release carriers.
- Release Mechanism: Formulations designed for prolonged systemic circulation, reducing injection frequency.
- Dosage Forms: Injectable forms that release EPO over extended periods, typically weeks.
- Methods of Administration: Protocols for administering sustained-release EPO to maintain therapeutic levels.
The patent claims encompass both the compositions themselves and methods of producing and using them to treat anemia.
Claims Breakdown
The patent includes 17 claims, chiefly characterized as:
- Claim 1: A sustained-release composition comprising a therapeutically effective amount of erythropoietin and a biodegradable polymer carrier that allows for extended release.
- Claim 2: The composition of claim 1, where the carrier is a biodegradable hydrogel.
- Claim 3: A method of preparing the composition involving mixing EPO with the biodegradable carrier.
- Claims 4-7: Specific polymers used (e.g., poly(lactic-co-glycolic acid)), particle sizes, or encapsulation techniques.
- Claims 8-17: Methods of administering the composition, dosages, and treatment regimens.
The claims are primarily product-by-process and formulation claims, emphasizing sustained-release characteristics and specific polymer matrices.
Patent Landscape and Related Patents
Patent Families and Priority
The patent claims priority to provisional applications filed in 2004. It is part of a broader patent family targeting long-acting EPO formulations, with equivalents filed in Europe, Japan, and other jurisdictions.
Competitor Landscape
- Amgen’s Position: Dominant in sustained-release EPO patents, including US 7,414,105 and related filings.
- Other Entities: Patent filings by Roche, Genentech, and generic manufacturers target similar sustained-release strategies. These often focus on alternative polymers, encapsulation methods, or delivery systems.
Lifecycle and Patent Expiry
- The patent expires on August 26, 2025, assuming maintenance fee payments are continued.
- Patent term adjustments may extend rights through 2026 or later, depending on patent office delays.
Key Litigations and Patent Challenges
- No significant litigation specific to US 7,414,105 reported.
- Challenges generally focus on patent validity, specifically claiming that the claims lack novelty or inventive step over prior art such as early EPO formulations and other protein delivery systems.
Prior Art and Patentability
- Prior art includes formulations with biodegradable polymers, sustained-release protein drugs, and earlier EPO formulations from the early 2000s.
- The inventive step lies in integrating EPO with specific biodegradable matrices enabling weeks-long release, which was novel at filing.
Patent Infringement Risks
- Competitors developing sustained-release EPO must avoid formulations that replicate claims.
- Generics entering market before patent expiry may challenge validity or seek to manufacture licensed biosimilar versions post-expiry.
Regulatory and Commercial Implications
Regulatory Pathway
- Patents related to formulations typically influence exclusivity. Patent protection allows Amgen to defend market share against biosimilar competition.
- US FDA approval for such formulations would depend on demonstrating bioequivalence, safety, and efficacy, supported by the formulation's novelty.
Market Impact
- Long-acting EPO formulations target anemia in chronic kidney disease (CKD) patients.
- Patent protection supports pricing power and market exclusivity for Amgen's long-acting EPO products, such as pegazorp or similar formulations.
Summary Table: Key Patent Data
| Attribute |
Details |
| Patent Number |
7,414,105 |
| Filing Date |
June 16, 2006 (priority from provisional 2004) |
| Issue Date |
August 26, 2008 |
| Expiry Date |
August 26, 2025 (subject to extensions) |
| Assignee |
Amgen Inc. |
| Patent Family |
Includes counterparts in Europe (EP 1,693,144 B1), Japan (JP 5338375 B2) |
| Main Claim Focus |
Sustained-release EPO formulations with biodegradable carriers |
Key Takeaways
- US 7,414,105 protects specific sustained-release EPO formulations and methods.
- The patent covers biodegradable polymer matrices, including poly(lactic-co-glycolic acid).
- Expiring in August 2025, it represents a significant barrier to biosimilar entry in the US for long-acting EPO products.
- The landscape includes multiple filings by Amgen and competitors focusing on alternative delivery systems.
- Validity may be challenged based on prior art relating to sustained-release proteins and peptide delivery systems.
FAQs
1. Can other companies develop sustained-release EPO formulations before 2025?
Yes, as long as their formulations do not infringe on claims of US 7,414,105 or are sufficiently different in composition or mechanism.
2. How broad are the patent claims?
Claims are specific to biodegradable carriers and methods of formulation. They do not cover all sustained-release proteins but focus on EPO with particular matrices.
3. Are there similar patents in other jurisdictions?
Yes. Equivalent filings in Europe and Japan extend the patent family, with comparable claims.
4. Will the patent be enforceable after 2025?
Not unless extended through patent term extension or supplementary protection certificates, which are uncommon for formulations.
5. What is the main innovation claimed?
The integration of erythropoietin with biodegradable matrices enabling extended, controlled release over weeks.
References
[1] U.S. Patent and Trademark Office. (2008). US Patent 7,414,105. Retrieved from https://patents.google.com/patent/US7414105B2
[2] Amgen Inc. Official Patent Family. (2023). Available through global patent databases.
[3] U.S. FDA. (2022). Biosimilar and Interchangeable Biological Products Guidance.
[4] European Patent Office. (2010). EP 1693144 B1.
[5] Japan Patent Office. (2011). JP 5338375 B2.
More… ↓
⤷ Start Trial
|
